앱토럼 그룹 (APM) 주가

앱토럼 그룹(APM)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $5.26 (+10.27%), 시가총액 $0.01B, 52주 최저~최고 $0.74 ~ $4.25.

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus

핵심 지표

• 현재가: $5.26 (+10.27%)
• 시가총액: $0.01B
• 52주 최저~최고: $0.74 ~ $4.25
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

앱토럼 그룹의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

앱토럼 그룹 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 0.30
• 순이익률: 0.00%
• 영업이익률: 0.00%

자주 묻는 질문